Transformative cardiovascular risk management solutions extend beyond traditional sectors to include federal and state correctional facilities, broker and benefits organizations, and risk bearing providers
February 16, 2024
Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
February 16, 2024 — Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company,…
Read More
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).
February 15, 2024
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment
February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and…
Read More
Research findings in a clinical trial led by a professor at the University of Tennessee Health Science Center’s College of Nursing are likely to dramatically change care and improve outcomes for patients suffering from acute stroke.
February 15, 2024
ZODIAC Clinical Trial Led by UT Health Science Center Professor Likely to Make Major Impact on Stroke Care
February 15, 2024 — Research findings in a clinical trial led by a professor at the University of Tennessee Health…
Read More
The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device
February 15, 2024
Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor
February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its…
Read More
Panel of independent experts reviewed data from the TRILUMINATE pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system
February 15, 2024
FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve
February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory…
Read More
NCDR’s CV ASC Registry Suite follows increases in ambulatory cardiac procedures, provides benchmarks
February 14, 2024
First-of-its-kind ACC Registry Tracks Cardiac Procedures Performed in Ambulatory Surgical Settings
February 14, 2024 — The American College of Cardiology’s newest registry offers data-driven insights on cardiac…
Read More
Novel bioresorbable scaffold system being developed for expanded indications
February 14, 2024
AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks
February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced…
Read More
The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or high blood pressure, in older adults without increasing their risk of low blood pressure episodes, according to a study published in the Feb. 2024 issue of the Journal of the American College of Cardiology (JACC).
February 14, 2024
DECIDE-Salt Study Finds Salt Substitutes Help to Maintain Healthy Blood Pressure in Older Adults
February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or…
Read More
In a groundbreaking study, researchers from The Texas Heart Institute, Baylor College of Medicine, Texas Children's Hospital, and the University of Texas Health Science Center McGovern Medical School have shed light on the underlying molecular cell states within transplanted pediatric hearts, paving the way for improved treatment strategies and enhancing the longevity of cardiac allografts.
February 13, 2024
Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts
February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children…
Read More
The company’s roster of clinical evidence continues to grow, with data highlights on expediting, broadening, and challenging current guidelines in stroke care
February 13, 2024
RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024
February 13, 2024 — RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow…
Read More
Butterfly iQ3 is built on the next-generation P4.3 Ultrasound-on-Chip technology with the world’s fastest digital data transfer, enhancing frame rates, frequency and new 3D imaging capabilities – all on a smaller, lighter and more ergonomically designed probe
February 13, 2024
Butterfly Network Launches Next-Generation Butterfly iQ3 in the United States
February 13, 2024 — Butterfly Network, Inc., a digital health company transforming care through the power of portable,…
Read More
Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging
February 13, 2024
Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease
February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease…
Read More
Millions of patients worldwide could benefit from better long-term outcomes by the company’s expansion into peripheral artery disease
February 12, 2024
Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease
February 12, 2024 — Sensome, a company pioneering the connected medical device revolution with the world’s smallest…
Read More
BIOTRONIK, a leader in implantable medical device technology, announced today they will solely supply their proprietary DX models for new single-chamber ICD implants moving forward
February 12, 2024
The Future of Single Chamber ICDs: BIOTRONIK Takes Unprecedented Market Stance with Proprietary DX Technology
February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely…
Read More
Results show statistically significant decreases in stroke volume, edema, and necrotic area versus controls
February 12, 2024
VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference
February 12, 2024 — VST Bio Corp. a leader in the development of innovative biologics to treat acute and chronic…
Read More
85-year-old patient with ischemic heart disease, who underwent cardiac MRI at 3 T
February 12, 2024
Free-breathing DL vs. Breath-hold Cardiac MRI Sequences in Ischemic Heart Disease
February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL)…
Read More
A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. and Allina Health.
February 12, 2024
Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure
February 12, 2023 — A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has…
Read More
On the final day of the American Stroke Association’s International Stroke Conference 2024, ISC 2024, findings from the EMBOLISE clinical trial were presented by Jason Davies, M.D., Ph.D., an associate professor in the departments of neurosurgery and biomedical informatics at the State University of New York, Buffalo.
February 09, 2024
ISC 2024 News: Late-Breaking Science Findings from EMBOLISE Clinical Trial Reveals Blocking Artery Supplying the Brain Covering After Subdural Hematoma Reduced Repeat Surgery
February 9, 2024 — Injection of a substance to block an artery feeding the dura (protective sack around the brain) —…
Read More
Primary effectiveness endpoint results show high revascularization rates of 93.9% mTICI 2b/3
February 09, 2024
MIVI Neuroscience Presents Primary Endpoint Results from the EvaQ Trial — at the 2024 International Stroke Conference
February 9, 2024 — MIVI Neuroscience, Inc. announced the primary endpoint results of its EvaQ Trial, a prospective,…
Read More
Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. Image by Getty.
February 09, 2024
Smidt Heart Institute Physicians Advance Transcatheter Tricuspid Valve Replacement
February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts:…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now